Plus Therapeutics Advances REYOBIQ Manufacturing with SpectronRx, Listing and Commercialization Risks Persist

What happened

Plus Therapeutics announced the initiation of manufacturing activities and technology transfer with SpectronRx under a Master Services Agreement, adding a second GMP site for REYOBIQ (rhenium-186 obisbemeda) alongside Radiomedix, with isotope supply from Telix Pharmaceuticals. This strengthens the multi-partner supply chain infrastructure for late-stage clinical manufacturing and pivotal trial readiness. However, the company still faces a critical Nasdaq minimum bid-price compliance deadline on May 11, 2026, with a reverse split as a likely backstop, which could further dilute shareholders. Additionally, CNSide test utilization metrics remain undisclosed, and management's >1,250 tests/year target lacks evidence of conversion from covered lives. The manufacturing progress is a necessary step but does not alter the near-term financing and listing overhang that dominate the stock's risk profile.

Implication

While the SpectronRx agreement de-risks REYOBIQ supply chain for pivotal trials, the stock's value hinges on resolving the May 11 bid-price compliance and demonstrating CNSide order velocity. Without these, dilution risk remains high and the base-case valuation of $0.32 per the DeepValue report is at risk. Investors should wait for evidence of Nasdaq compliance and CNSide utilization before adding exposure.

Thesis delta

The manufacturing milestone lowers supply chain execution risk but does not change the dominant drivers: Nasdaq compliance and CNSide conversion. The wait rating is reaffirmed; the stock remains a financing story until these gates are cleared.